Varenicline Tartrate Kit
Product Images NDC 85742-017

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Varenicline Tartrate (NDC 85742-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Containerlabel1mg (Containerlabel1mg)

Varenicline Tablets 1 mg film-coated oral tablets label from Kanchan Healthcare Inc. The label includes dosing information stating each tablet contains 1 mg varenicline base, storage instructions, manufacturer and distributor addresses, a barcode, and a pack count of 56 tablets. The label emphasizes prescription use and child-resistant packaging.*

FDA Label Image

Containerlabelpoint5mg (Containerlabelpoint5mg)

Label for Varenicline Tablets 0.5 mg, film-coated oral tablets. The label indicates a quantity of 56 tablets and includes storage instructions at controlled room temperature. Manufactured by Medley Pharmaceuticals Ltd., India, and labeled for Kanchan Healthcare Inc., USA. The label features dosage information and a barcode.*

FDA Label Image

Continuingmonthbox (Continuingmonthbox)

Packaging label for Varenicline Tablets Continuing Month Box containing 1 mg strength tablets. The box contains 56 film-coated oral tablets intended for a 4-week supply. The label specifies it as prescription-only (Rx only) and includes the NDC 85742-016-16. Labeler information shows Kanchan Healthcare Inc.*

FDA Label Image

Continuingpack (Continuingpack)

Varenicline Tablets Continuing Pack carton label from Kanchan Healthcare Inc. The package contains 4 continuing weeks of tablets, each week comprising 1 mg strength tablets, totaling 56 tablets. The label includes dosage form as film-coated oral tablets and features dosing instructions, storage information, and a barcode. The product is Rx only with NDC 85742-016-16.*

FDA Label Image

Startingmonthbox (Startingmonthbox)

Packaging label for Varenicline Tablets Starting Month Box by Kanchan Healthcare Inc. The box contains a 4-week supply including 0.5 mg tablets for the first week (11 tablets) and 1 mg tablets for the next three weeks (42 tablets). The label instructs to dispense the accompanying Medication Guide with the product.*

FDA Label Image

Startingpack (Startingpack)

Packaging label for Varenicline Tablets Starting Pack by Kanchan Healthcare Inc. It includes a violet section for starting week tablets (0.5 mg, 11 tablets) and pink sections for continuing weeks (1 mg, 42 tablets total) arranged in blister cards labeled with days of dosing. The label shows instructions to use the violet blister card first, storage conditions, dosing notes, manufacturer and labeler information, and an NDC number 85742-017-17.*

FDA Label Image

Varenicline-01 (Varenicline 01)

Chemical structure diagram showing the molecular arrangement of varenicline tartrate, the active ingredient in VARENICLINE TARTRATE tablets by Kanchan Healthcare Inc.*

FDA Label Image

Varenicline-02 (Varenicline 02)

A bar chart titled 'Continuous Abstinence, Weeks 9 through 12' displays data across five studies comparing abstinence rates between Varenicline tartrate (0.5 mg and 1.0 mg doses), bupropion, placebo, and varenicline flexible dosing. Each study is shown with bars representing different treatment groups and their respective abstinence percentages.*

FDA Label Image

Varenicline-03 (Varenicline 033)

A bar graph titled 'Figure 2: Continuous Abstinence, Weeks 9 through 52,' showing percentage abstinence rates across four different studies. The graph compares Varenicline Tartrate (0.5 mg and 1.0 mg doses, including flexible dosing) to placebo and bupropion SR 150 mg BID, with error bars indicating variability in the data.*

FDA Label Image

Varenicline-04 (Varenicline 04)

A line graph comparing the percentage of continuous abstinent participants over nontreatment follow-up weeks between Varenicline 1.0 mg BID and placebo. The x-axis represents nontreatment follow-up in weeks, and the y-axis shows the percentage of continuous abstinent individuals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.